December 3, 2014. Research has implicated endocrine-disrupting chemicals in cancer, infertility, and other health problems. We must be able to quickly identify such agents in order to prevent them from entering our food and environment, and from affecting our health for generations to come.
Read More »On Health Policy
NCHR Testimony at FDA Risk Communication Advisory Committee on Fish Consumption
November 3, 2014. NCHR states that most consumers don’t want to have a long list of exactly what kind of fish to eat and what to avoid. If pregnant and breastfeeding women have avoided fish for themselves and for their young children, it’s because the messages they were getting were confusing. Come up with phrases that are easy to remember and and messages that are straightforward.
Read More »NCHR Comments on Social Media Platforms Presenting Risk and Benefit Information for Prescription Drugs and Medical Devices
October 29, 2014. NCHR states that patients and consumers increasingly rely on social media and the internet as sources of health and medical information that influence their decisions to seek medical care, and clarity is important.
Read More »NCHR Comments on FDA Safety and Innovation Act Action Plan
October 21, 2014. NCHR strongly supports inclusion of separate analysis of safety and effectiveness for demographic subgroups in clinical trials for drugs and devices. It is essential that methodologically sound data about how drugs and devices work in these groups be conducted and made publicly available.
Read More »NCHR Comments on De Novo Classification Process
October 14, 2014. As members of the Patient, Consumer, and Public Health Coalition, we have serious reservations about the use of the de novo classification process for implants, life-sustaining, and life-saving devices. We believe that all such high-risk devices should be Class III devices reviewed through the more rigorous PMA process.
Read More »